Skip to content

    Divi's Lab.

    DIVISLAB
    Healthcare·12 Nov 2025
    Management Summary

    Divi's Laboratories reported a strong Q2 FY26, with consolidated total income growing 17% YoY to ₹2,860 crores and PAT increasing 35.1% to ₹689 crores. The custom synthesis segment was a key growth driver, contributing 56% to the product mix, while the generics business continued to face pricing pressures. The company is actively investing in capacity expansion, with H1 FY26 capex at ₹1,550 crores and full-year capex expected to exceed ₹2,000 crores, focusing on new projects, peptide synthesis, and Unit 3 operations.

    Highlights

    5
    • Consolidated total income for Q2 FY26 was ₹2,860 crores, a 17% increase from ₹2,444 crores in Q2 FY25.

    • Profit after tax for Q2 FY26 was ₹689 crores, up 35.1% from ₹510 crores in Q2 FY25.

    • Product mix for Q2 FY26 showed 56% from custom synthesis, reflecting high engagement levels and multiple projects advancing.

    • Material consumption improved to 39.5% of sales revenue in Q2 FY26, consistent with recent trends.

    • The company recorded a forex gain of ₹63 crores in Q2 FY26.

    Concerns

    3
    • Generic business continues to face pricing pressures, with low single-digit decline in that segment.

    • Management expects no moderation in the pace of price erosion for generics in the next 2 quarters.

    • Specific details on the impact of patent expiry for a key custom synthesis project were not disclosed due to confidentiality.

    What Changed1

    vs Q3 FY26

    Guidance items4 → 8 (+4)

    Key financials

    Single quarter

    06 metrics
    1. 01Total Income₹2,860 Cr+17.0%YoY
    2. 02Profit Before Tax₹912 Cr+26.3%YoY
    3. 03Profit After Tax₹689 Cr+35.1%YoY
    4. 04Material Consumption39.5%
    5. 05Generics Product Mix44%

    Capital allocation

    2
    high confidence
    CategoryHeadline
    Capex

    ₹2,000 crores

    raised — ongoing projects and capacity creation

    Liquidity

    Cash ₹3,451 crores

    Receivables stood at ₹2,614 crores and inventories at ₹3,433 crores as of September 30, 2025.

    Guidance & targets

    8
    CategoryTargetPriority
    Capex
    FY26 Capex Spend
    higher than ₹2,000 crores
    High
    Revenue
    Constant Currency Revenue Growth
    around 10.79%
    Medium
    Commercialization
    Commercial benefit from CS projects
    next 1 to 2 years
    Medium
    New Projects Revenue
    Revenue from 3 announced projects
    1 to 2 years
    Medium
    Generic Business
    Stabilization of generic business
    stabilize and come back to normal
    Low
    Generic Business
    Pace of generic price erosion
    no improvement
    High
    Product Launch
    Commercialization of Contrast Media products
    soon
    Medium
    Product Launch
    Regulatory approvals for Gadolinium compounds
    at least 1 year
    Medium

    Generic business stabilization

    Next few quarters
    CurrentWeak, low single-digit decline, ongoing pricing pressure
    TargetStabilization, return to normal

    Why it matters

    Key to overall revenue growth and margin recovery, as generics still form 44% of the product mix.

    But we are hopeful, like I explained in the last call, we're hopeful in the next few quarters, it may stabilize and things may come back to normal.

    How to verify

    key_financials.segment_breakdown[name='Generics'].metrics[label='Revenue Growth']

    Risks & concerns

    4
    RiskSeverity

    Generic pricing pressure

    Ongoing pricing pressure in the generic segment, impacting revenue visibility, though volumes are stable due to backward integration.Both acknowledged

    medium

    Regulatory approvals for new custom synthesis projects

    Timelines for commercialization of new projects (1-2 years) are contingent on obtaining all necessary regulatory approvals.Management acknowledged

    medium

    Patent expiry for existing custom synthesis projects

    Analyst raised concerns about patent expiry for a key custom synthesis project, which management could not comment on due to confidentiality, implying potential volume/revenue impact.Analyst deflected

    medium

    Raw material cost volatility due to geopolitical factors

    Potential influence of US tariffs on China suppliers and Russia sanctions on certain raw materials, mitigated by diversified sourcing, inventory, and backward integration.Management acknowledged

    low

    Q&A highlights

    8

    “I'm sorry, I cannot comment on any specific product, customer impact or volumes. Because I'm bound by confidentiality.”

    Analyst sought to understand the potential volume impact of a known patent expiry on a key custom synthesis project, but management declined to provide specifics due to confidentiality.

    asked by Amay

    3 min read8 chapters

    Detailed Narrative

    01

    Q2 FY26 Financial Performance Overview

    Divi's Laboratories reported a consolidated total income of ₹2,860 crores for Q2 FY26, marking a 17% increase year-on-year from ₹2,444 crores. Profit before tax rose to ₹912 crores, up from ₹722 crores in Q2 FY25, while profit after tax saw a significant jump of 35.1% to ₹689 crores. For the first half of FY26, total income reached ₹5,389 crores, a 16% increase from the previous fiscal year's ₹4,640 crores.

    02

    Generic Business Dynamics and Mitigation Strategies

    The generic API segment continues to experience pricing pressures, resulting in a low single-digit decline, though the company has maintained consistent volumes and customer base. To manage input costs effectively and sustain market share, Divi's leverages its backward integration model, with Unit 3 in Kakinada supporting in-house production of starting materials and intermediates. Management hopes for stabilization in the generic business within the next few quarters, but anticipates no improvement in price erosion for the next two quarters.

    03

    Custom Synthesis Momentum and Pipeline

    Custom synthesis remains a strong growth driver, contributing 56% to the product mix in Q2 FY26. The company is seeing high engagement levels with global innovators, with multiple projects advancing through development and validation stages. Commercial manufacturing from some of these projects is expected to commence within the next 1 to 2 years, contingent on regulatory approvals. Divi's emphasizes its long-term customer relationships and comprehensive capabilities beyond just pricing as key competitive advantages.

    04

    Peptide and Nutraceutical Growth Drivers

    Divi's is experiencing strong momentum in peptide synthesis, having inaugurated a peptide center of excellence and actively engaging with big pharmas on Phase I, II, and III programs. The long-term strategy aims to establish Divi's as a world leader in complex peptide manufacturing. Additionally, the nutraceutical segment contributed ₹242 crores in Q2 FY26 and ₹492 crores in H1 FY26, leveraging its manufacturing strength in carotenoids and other value-added ingredients to capitalize on the growing global focus on health and wellness.

    05

    Capacity Expansion and Technology Adoption

    The company is executing three major capex programs backed by long-term supply commitments. H1 FY26 capex spend was ₹1,550 crores, and the full-year FY26 capex is projected to be higher than the initial guidance of ₹2,000 crores. These investments are focused on implementing new technologies like flow chemistry, biocatalysis, and green chemistry, expanding capacities, and advancing key strategic projects to enhance sustainability and efficiency.

    06

    Unit 3 Operations and Backward Integration

    Unit 3 in Kakinada, which became operational earlier this year, is crucial for supporting Divi's supply chain by enabling in-house production of starting materials and intermediates. This also frees up GMP-compliant capacity at other units. The company plans to begin qualification of in-house APIs at Unit 3 in the near future, with appropriate qualifications and Drug Master File submissions expected in the next few quarters, moving towards regular GMP production.

    07

    Contrast Media and Gadolinium Compounds

    Divi's is actively progressing on its Contrast Media scale-up, working on validations with major players and expecting commercialization soon. For Gadolinium compounds, the company is collaborating with innovators on Phase III molecules, but regulatory approvals are anticipated to take at least one year before any results are seen. Management remains hopeful for positive outcomes in both these specialized areas.

    08

    Community Initiatives

    Divi's continues its commitment to community development through various initiatives. Education programs reach thousands of students, and efforts in providing safe drinking water have reached 8 lakh people. The company emphasizes inclusive development through targeted interventions in nutrition, infrastructure, and scholarships, reflecting its belief in business success hand-in-hand with social progress.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.